Currently, there are 49.22M common shares owned by the public and among those 40.44M shares have been available to trade.
The company’s stock has a 5-day price change of -2.29% and -19.62% over the past three months. AXSM shares are trading 24.18% year to date (YTD), with the 12-month market performance up to 34.50% higher. It has a 12-month low price of $64.11 and touched a high of $139.13 over the same period. AXSM has an average intraday trading volume of 729.71K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.43%, -4.68%, and 4.23% respectively.
Institutional ownership of Axsome Therapeutics Inc (NASDAQ: AXSM) shares accounts for 76.19% of the company’s 49.22M shares outstanding.
It has a market capitalization of $5.17B and a beta (3y monthly) value of 0.48. The earnings-per-share (ttm) stands at -$5.77. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.40% over the week and 2.19% over the month.
Earnings per share for the fiscal year are expected to increase by 42.55%, and 150.13% over the next financial year.
Looking at the support for the AXSM, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on April 07, 2025, with the firm’s price target at $200. Deutsche Bank coverage for the Axsome Therapeutics Inc (AXSM) stock in a research note released on February 11, 2025 offered a Buy rating with a price target of $176. Mizuho was of a view on December 31, 2024 that the stock is Outperform, while Wells Fargo gave the stock Overweight rating on September 03, 2024, issuing a price target of $140. BofA Securities on their part issued Buy rating on August 06, 2024.
